TY - JOUR
T1 - Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab
T2 - A single-center retrospective study in Japan
AU - Otsuka, Masaki
AU - Sugihara, Satoru
AU - Mori, Shoichiro
AU - Hamada, Kengo
AU - Sasaki, Yosuke
AU - Yoshikawa, Shusuke
AU - Kiyohara, Yoshio
N1 - Funding Information:
The authors are grateful to the medical and nursing colleagues in Shizuoka Cancer Center. In addition, the authors thank the patients and their families who participated in this study.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Immune-related adverse events (irAE) were reported to be associated with better outcomes in various cancers treated with the immune checkpoint inhibitor nivolumab. Considering that their development depends on host immune activation, irAE may reflect antitumor response in mucosal melanoma (MM). This single-center retrospective study including patients with advanced MM receiving nivolumab monotherapy between August 2014 and September 2018 investigated whether the development of irAE was associated with clinical efficacy. The study patients were divided into those with and without irAE, and treatment efficacy and safety were evaluated. The study cohort of 27 patients included 20 (74%), six (22%) and one (4%) patient with primary MM in the head and neck, genitourinary and anorectal regions, respectively. The irAE onset was not significantly associated with the objective response rate in patients while it was significantly associated with the disease control rate. The median progression-free survival in patients with and without irAE was 301 and 63 days, respectively. The median overall survival (OS) in patients with and without irAE was 723 and 199 days, respectively. According to the timing of irAE onset, the OS was better in seven patients who developed irAE after 180 days than in nine patients who developed irAE within 180 days. Although 16 patients (59%) experienced any grade irAE, including three (11%) with grade 3 or more irAE, there were no treatment-related deaths. These results indicated that the development of irAE may correlate with improved survival in patients with MM treated with nivolumab monotherapy. Further studies are necessary to confirm these findings.
AB - Immune-related adverse events (irAE) were reported to be associated with better outcomes in various cancers treated with the immune checkpoint inhibitor nivolumab. Considering that their development depends on host immune activation, irAE may reflect antitumor response in mucosal melanoma (MM). This single-center retrospective study including patients with advanced MM receiving nivolumab monotherapy between August 2014 and September 2018 investigated whether the development of irAE was associated with clinical efficacy. The study patients were divided into those with and without irAE, and treatment efficacy and safety were evaluated. The study cohort of 27 patients included 20 (74%), six (22%) and one (4%) patient with primary MM in the head and neck, genitourinary and anorectal regions, respectively. The irAE onset was not significantly associated with the objective response rate in patients while it was significantly associated with the disease control rate. The median progression-free survival in patients with and without irAE was 301 and 63 days, respectively. The median overall survival (OS) in patients with and without irAE was 723 and 199 days, respectively. According to the timing of irAE onset, the OS was better in seven patients who developed irAE after 180 days than in nine patients who developed irAE within 180 days. Although 16 patients (59%) experienced any grade irAE, including three (11%) with grade 3 or more irAE, there were no treatment-related deaths. These results indicated that the development of irAE may correlate with improved survival in patients with MM treated with nivolumab monotherapy. Further studies are necessary to confirm these findings.
KW - Japanese
KW - immune-related adverse event
KW - immunotherapy
KW - mucosal melanoma
KW - nivolumab
UR - http://www.scopus.com/inward/record.url?scp=85078758893&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078758893&partnerID=8YFLogxK
U2 - 10.1111/1346-8138.15246
DO - 10.1111/1346-8138.15246
M3 - Article
C2 - 31984569
AN - SCOPUS:85078758893
VL - 47
SP - 356
EP - 362
JO - Journal of Dermatology
JF - Journal of Dermatology
SN - 0385-2407
IS - 4
ER -